{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:50:48Z","timestamp":1788288648055,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11934-025-01297-x","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:45:47Z","timestamp":1764740747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urologic Symptom Management in Parkinson\u2019s Disease - Current Treatments and Emerging Directions - Systematic Review"],"prefix":"10.1007","volume":"26","author":[{"given":"Omer","family":"Anis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar","family":"Anis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles M.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teixeira-dos-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Ivary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Trump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard B.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"1297_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.914963","volume":"13","author":"D Pang","year":"2022","unstructured":"Pang D, Gao Y, Liao L. Functional brain imaging and central control of the bladder in health and disease. Front Physiol. 2022;13:914963.","journal-title":"Front Physiol"},{"key":"1297_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.parkreldis.2016.10.024","volume":"35","author":"C McDonald","year":"2017","unstructured":"McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson\u2019s disease: prevalence, aetiology and management. Parkinsonism Relat Disord. 2017;35:8\u201316.","journal-title":"Parkinsonism Relat Disord"},{"key":"1297_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.977572","volume":"14","author":"FF Li","year":"2022","unstructured":"Li FF, Cui YS, Yan R, Cao SS, Feng T. Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2022;14:977572.","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"1297_CR4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3233\/JPD-191806","volume":"10","author":"C Jia","year":"2020","unstructured":"Jia C, Cui X, Yoshimura N, Mao W, Xu E, Wang Q, et al. Assessment and management of urinary dysfunction in 187 patients with parkinson\u2019s disease. J Parkinsons Dis. 2020;10(3):993\u20131001.","journal-title":"J Parkinsons Dis"},{"key":"1297_CR5","doi-asserted-by":"publisher","unstructured":"Gao L, Wang M, Zhou M, Yin W, Cao X. Impact of deep brain stimulation on urogenital function in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Neurol. 2024 [cited 2025 May 31];15. Available from: https:\/\/www.frontiersin.org\/journals\/neurology\/articles\/https:\/\/doi.org\/10.3389\/fneur.2024.1397344\/full","DOI":"10.3389\/fneur.2024.1397344\/full"},{"key":"1297_CR6","unstructured":"National Institute of Health. Study Quality Assessment Tools. [cited 2025 Mar 1]. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"issue":"18","key":"1297_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1212\/01.wnl.0000260605.12506.86","volume":"68","author":"L Brusa","year":"2007","unstructured":"Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, et al. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology. 2007;68(18):1455\u20139.","journal-title":"Neurology"},{"key":"1297_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116625","volume":"410","author":"L Brusa","year":"2020","unstructured":"Brusa L, Ponzo V, Stefani A, Ceravolo R, Palermo G, Agr\u00f2 EF, et al. Extended release Levodopa at bedtime as a treatment for nocturiain Parkinson\u2019s disease: an open label study. J Neurol Sci. 2020;410:116625.","journal-title":"J Neurol Sci"},{"issue":"5","key":"1297_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/mds.10403","volume":"18","author":"T Uchiyama","year":"2003","unstructured":"Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single Levodopa dose on micturition disturbance in Parkinson\u2019s disease patients with the wearing-off phenomenon. Mov Disord. 2003;18(5):573\u20138.","journal-title":"Mov Disord"},{"issue":"1","key":"1297_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/mds.22519","volume":"25","author":"R Sakakibara","year":"2010","unstructured":"Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson\u2019s disease. Mov Disord. 2010;25(1):2\u201312.","journal-title":"Mov Disord"},{"key":"1297_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2020.08.032","volume":"79","author":"E J\u00f6rg","year":"2020","unstructured":"J\u00f6rg E, Sartori AM, Hofer AS, Baumann CR, Kessler TM. Deep brain stimulation effects on lower urinary tract function: systematic review and meta-analysis. Parkinsonism Relat Disord. 2020;79:65\u201372.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1297_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/ana.10806","volume":"55","author":"C Seif","year":"2004","unstructured":"Seif C, Herzog J, van der Horst C, Schrader B, Volkmann J, Deuschl G, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol. 2004;55(1):118\u201320.","journal-title":"Ann Neurol"},{"issue":"8","key":"1297_CR13","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00345-019-02981-7","volume":"38","author":"T Yonguc","year":"2020","unstructured":"Yonguc T, Sefik E, Inci I, Kusbeci OY, Celik S, Ayd\u0131n ME, et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson\u2019s disease. World J Urol. 2020;38(8):2013\u20139.","journal-title":"World J Urol"},{"issue":"5","key":"1297_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.025","volume":"21","author":"TA Zesiewicz","year":"2015","unstructured":"Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, et al. Randomized, controlled pilot trial of Solifenacin succinate for overactive bladder in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21(5):514\u201320.","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"1297_CR15","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jfma.2022.04.004","volume":"121","author":"SF Chen","year":"2022","unstructured":"Chen SF, Chuang YC, Wang CC, Liao CH, Kuo HC. Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system disorders\u2014a cohort study. J Formos Med Assoc. 2022;121(10):2101\u20138.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1297_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.21037\/tau-23-378","volume":"13","author":"C Jia","year":"2024","unstructured":"Jia C, Cui X, Ou T. Efficacy of medication for overactive bladder symptoms in 70 patients with Parkinson\u2019s disease. Transl Androl Urol. 2024;13(1):64\u201371.","journal-title":"Transl Androl Urol"},{"issue":"3","key":"1297_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","volume":"175","author":"SL Gray","year":"2015","unstructured":"Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"1297_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/11597530-000000000-00000","volume":"29","author":"MB Chancellor","year":"2012","unstructured":"Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW. Blood\u2013brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29(4):259\u201373.","journal-title":"Drugs Aging"},{"issue":"2","key":"1297_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/iju.iju_352_23","volume":"40","author":"B Welk","year":"2024","unstructured":"Welk B. The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfunction: a narrative review. Indian J Urol. 2024;40(2):82\u20137.","journal-title":"Indian J Urol"},{"issue":"10","key":"1297_CR20","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00228-015-1919-7","volume":"71","author":"U Lertxundi","year":"2015","unstructured":"Lertxundi U, Isla A, Solinis MA, Domingo-Echaburu S, Hernandez R, Peral-Aguirregoitia J, et al. Anticholinergic burden in Parkinson\u2019s disease inpatients. Eur J Clin Pharmacol. 2015;71(10):1271\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1297_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/mdc3.13032","volume":"7","author":"R Rajan","year":"2020","unstructured":"Rajan R, Saini A, Verma B, Choudhary N, Gupta A, Vishnu VY, et al. Anticholinergics may carry significant cognitive and gait burden in parkinson\u2019s disease. Mov Disord Clin Pract. 2020;7(7):803\u20139.","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"1297_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3233\/JPD-150664","volume":"5","author":"AJ Yarnall","year":"2015","unstructured":"Yarnall AJ, Lawson RA, Duncan GW, Breen DP, Khoo TK, Brooks D, et al. Anticholinergic load: is there a cognitive cost in early Parkinson\u2019s disease? J Parkinsons Dis. 2015;5(4):743\u20137.","journal-title":"J Parkinsons Dis"},{"key":"1297_CR23","doi-asserted-by":"crossref","unstructured":"Ahmad S, Reyes JVM, Lieber J. Oxybutynin-Induced Hyperthermia in a Patient With Parkinson\u2019s Disease. Cureus. 2021. [cited 2025 May 11]; Available from: https:\/\/www.cureus.com\/articles\/56597-oxybutynin-induced-hyperthermia-in-a-patient-with-parkinsons-disease","DOI":"10.7759\/cureus.14701"},{"key":"1297_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105822","volume":"115","author":"DS Abraham","year":"2023","unstructured":"Abraham DS, Pham Nguyen TP, Newcomb CW, Gray SL, Hennessy S, Leonard CE, et al. Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease. Parkinsonism Relat Disord. 2023;115:105822.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1297_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/21681805.2021.1990994","volume":"56","author":"M Moussa","year":"2022","unstructured":"Moussa M, Chakra MA, Dabboucy B, Fares Y, Dellis A, Papatsoris A. The safety and effectiveness of mirabegron in Parkinson\u2019s disease patients with overactive bladder: a randomized controlled trial. Scand J Urol. 2022;56(1):66\u201372.","journal-title":"Scand J Urol"},{"issue":"1","key":"1297_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/nau.24552","volume":"40","author":"SY Cho","year":"2021","unstructured":"Cho SY, Jeong SJ, Lee S, Kim J, Lee SH, Choo MS, et al. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson\u2019s disease: a double-blind, randomized placebo\u2010controlled trial (Parkinson\u2019s disease overactive bladder Mirabegron, PaDoMi study). Neurourol Urodyn. 2021;40(1):286\u201394.","journal-title":"Neurourol Urodyn"},{"issue":"11","key":"1297_CR27","volume":"14","author":"A Madan","year":"2022","unstructured":"Madan A, Brown T, Ray S, Agarwal P, Roy-Faderman I, Burdick D. A novel trial of mirabegron and behavioral modification including pelvic floor exercise for overactive bladder in Parkinson\u2019s disease (MAESTRO). Cureus. 2022;14(11):e31818.","journal-title":"Cureus"},{"issue":"4","key":"1297_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4081\/aiua.2022.4.492","volume":"94","author":"R Bapir","year":"2022","unstructured":"Bapir R, Bhatti KH, Eliwa A, Garc\u00eda-Perdomo HA, Gherabi N, Hennessey D, et al. Efficacy of overactive neurogenic bladder treatment: a systematic review of randomized controlled trials. Arch Ital Urol Androl. 2022;94(4):492\u2013506.","journal-title":"Arch Ital Urol Androl"},{"key":"1297_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419843458","volume":"12","author":"M Gubbiotti","year":"2019","unstructured":"Gubbiotti M, Conte A, Di Stasi SM, Tambasco N, Giannantoni A. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson\u2019s disease: a pilot study. Ther Adv Neurol Disord. 2019;12:1756286419843458.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1297_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000500349","volume":"103","author":"MA Soebadi","year":"2019","unstructured":"Soebadi MA, Hakim L, Van der Aa F, De Ridder D. Real-Life data on mirabegron in neurogenic bladder dysfunction. Urol Int. 2019;103(2):195\u2013201.","journal-title":"Urol Int"},{"key":"1297_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.parkreldis.2018.07.005","volume":"57","author":"B Peyronnet","year":"2018","unstructured":"Peyronnet B, Vurture G, Palma JA, Malacarne DR, Feigin A, Sussman RD, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord. 2018;57:22\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"1297_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2016.03.009","volume":"27","author":"AG Murchison","year":"2016","unstructured":"Murchison AG, Fletcher C, Cheeran B. Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson\u2019s disease on DBS (GPi). Parkinsonism Relat Disord. 2016;27:107\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"1297_CR33","first-page":"304","volume":"26","author":"ES Malsin","year":"2019","unstructured":"Malsin ES, Coleman JM, Wolfe LF, Lam AP. Respiratory dysfunction following initiation of mirabegron: a case report. Respir Med Case Rep. 2019;26:304\u20136.","journal-title":"Respir Med Case Rep"},{"issue":"6","key":"1297_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/luts.12503","volume":"15","author":"M Togo","year":"2023","unstructured":"Togo M, Kitta T, Chiba H, Higuchi M, Kusakabe N, Ouchi M, et al. Effects of a new selective \u03b23 -adrenoceptor agonist, vibegron, on bladder and urethral function in a rat model of parkinson\u2019s disease. LUTS: Lower Urinary Tract Symptoms. 2023;15(6):265\u201370.","journal-title":"LUTS: Lower Urinary Tract Symptoms"},{"issue":"1","key":"1297_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003985","volume":"212","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT, et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11\u201320.","journal-title":"J Urol"},{"issue":"1","key":"1297_CR36","first-page":"e53309","volume":"16","author":"E Slouha","year":"2024","unstructured":"Slouha E, Ibrahim F, Esposito S, Mursuli O, Rezazadah A, Clunes LA, et al. Botulinum toxin for the management of parkinson\u2019s disease: A systematic review. Cureus. 2024;16(1):e53309.","journal-title":"Cureus"},{"issue":"8","key":"1297_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.parkreldis.2010.06.006","volume":"16","author":"H Kulaksizoglu","year":"2010","unstructured":"Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with parkinsons\u2019s disease. Parkinsonism Relat Disord. 2010;16(8):531\u20134.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"1297_CR38","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","volume":"182","author":"A Giannantoni","year":"2009","unstructured":"Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson\u2019s disease and multiple system atrophy. J Urol. 2009;182(4):1453\u20137.","journal-title":"J Urol"},{"issue":"3","key":"1297_CR39","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","volume":"186","author":"A Giannantoni","year":"2011","unstructured":"Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson\u2019s disease and refractory overactive bladder. J Urol. 2011;186(3):960\u20134.","journal-title":"J Urol"},{"issue":"1","key":"1297_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.urology.2013.09.017","volume":"83","author":"RU Anderson","year":"2014","unstructured":"Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson\u2019s disease. Urology. 2014;83(1):22\u20137.","journal-title":"Urology"},{"issue":"1","key":"1297_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-016-0174-2","volume":"16","author":"SC Kn\u00fcpfer","year":"2016","unstructured":"Kn\u00fcpfer SC, Schneider SA, Averhoff MM, Naumann CM, Deuschl G, J\u00fcnemann KP, et al. Preserved micturition after intradetrusor OnabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson\u2019s disease. BMC Urol. 2016;16(1):55.","journal-title":"BMC Urol"},{"issue":"8","key":"1297_CR42","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/nau.23717","volume":"37","author":"G Vurture","year":"2018","unstructured":"Vurture G, Peyronnet B, Feigin A, Biagioni MC, Gilbert R, Rosenblum N, et al. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson\u2019s disease. Neurourol Urodyn. 2018;37(8):2669\u201377.","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"1297_CR43","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.neurom.2022.01.019","volume":"25","author":"MD Smith","year":"2022","unstructured":"Smith MD, Tenison E, Hashim H, Ben-Shlomo Y, Henderson EJ. Neuromodulation for storage lower urinary tract symptoms in Parkinson disease: a systematic review. Neuromodulation: Technology at the Neural Interface. 2022;25(8):1076\u201385.","journal-title":"Neuromodulation: Technology at the Neural Interface"},{"issue":"8","key":"1297_CR44","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/nau.24954","volume":"41","author":"CN Wang","year":"2022","unstructured":"Wang CN, Chung DE. Neuromodulation for lower urinary tract symptoms in special populations. Neurourol Urodyn. 2022;41(8):1948\u201357.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"1297_CR45","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/nau.24900","volume":"41","author":"S Martin","year":"2022","unstructured":"Martin S, Zillioux J, Goldman HB. Is sacral neuromodulation effective in patients with Parkinson\u2019s disease? A retrospective review. Neurourol Urodyn. 2022;41(4):955\u201361.","journal-title":"Neurourol Urodyn"},{"key":"1297_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.urology.2020.06.063","volume":"144","author":"DR Greenberg","year":"2020","unstructured":"Greenberg DR, Sohlberg EM, Zhang CA, Santini VE, Comiter CV, Enemchukwu EA. Sacral nerve stimulation in Parkinson\u2019s disease patients with overactive bladder symptoms. Urology. 2020;144:99\u2013105.","journal-title":"Urology"},{"issue":"20","key":"1297_CR47","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025941","volume":"100","author":"DY Yang","year":"2021","unstructured":"Yang DY, Zhao LN, Qiu MX. Treatment for overactive bladder: a meta-analysis of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation. Medicine. 2021;100(20):e25941.","journal-title":"Medicine"},{"key":"1297_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211063059","volume":"13","author":"MU Ali","year":"2022","unstructured":"Ali MU, Fong KNK, Kannan P, Bello UM, Kranz GS. Effects of nonsurgical, minimally or noninvasive therapies for urinary incontinence due to neurogenic bladder: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2022;13:20406223211063059.","journal-title":"Ther Adv Chronic Dis"},{"key":"1297_CR49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.urology.2015.09.026","volume":"87","author":"S Kabay","year":"2016","unstructured":"Kabay S, Canbaz Kabay S, Cetiner M, Mestan E, Sevim M, Ayas S, et al. The clinical and urodynamic results of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson\u2019s disease. Urology. 2016;87:76\u201381.","journal-title":"Urology"},{"issue":"1","key":"1297_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/nau.20593","volume":"28","author":"SC Kabay","year":"2009","unstructured":"Kabay SC, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson\u2019s disease. Neurourol Urodyn. 2009;28(1):62\u20137.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"1297_CR51","first-page":"265","volume":"50","author":"MY El-Senousy","year":"2013","unstructured":"El-Senousy MY, Shawky E, Fayed HA, Taha RM. Efficacy of posterior tibial nerve stimulation on detrusor overactivity of idiopathic Parkinson\u2019s disease patients clinical and urodynamic evaluation. Egypt J Neurol Psychiatry Neurosurg. 2013;50(3):265\u201370.","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"issue":"1","key":"1297_CR52","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/nau.24595","volume":"40","author":"TG Araujo","year":"2021","unstructured":"Araujo TG, Schmidt AP, Sanches PRS, Silva Junior DP, Rieder CRM, Ramos JGL. Transcutaneous tibial nerve home stimulation for overactive bladder in women with Parkinson\u2019s disease: a randomized clinical trial. Neurourol Urodyn. 2021;40(1):538\u201348.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"1297_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac114","volume":"51","author":"D McClurg","year":"2022","unstructured":"McClurg D, Elders A, Hagen S, Mason H, Booth J, Cunnington AL, et al. Stimulation of the tibial nerve\u2014a randomised trial for urinary problems associated with Parkinson\u2019s\u2014the STARTUP trial. Age Ageing. 2022;51(6):afac114.","journal-title":"Age Ageing"},{"issue":"1","key":"1297_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06827-3","volume":"23","author":"MD Smith","year":"2022","unstructured":"Smith MD, Tenison E, Drake MJ, Ben-Shlomo Y, Henderson EJ. Stimulation of the tibial nerve repetitively to improve incontinence in Parkinson\u2019s electronically (STRIPE trial): a randomised control trial of tibial nerve stimulation for bladder symptoms in Parkinson\u2019s disease using a self-contained wearable device. Trials. 2022;23(1):912.","journal-title":"Trials"},{"issue":"8","key":"1297_CR55","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/mdc3.13347","volume":"8","author":"MJ Barrett","year":"2021","unstructured":"Barrett MJ, Sargent L, Nawaz H, Weintraub D, Price ET, Willis AW. Antimuscarinic anticholinergic medications in Parkinson disease: to prescribe or deprescribe? Mov Disord Clin Pract. 2021;8(8):1181\u20138.","journal-title":"Mov Disord Clin Pract"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-025-01297-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:03:50Z","timestamp":1767985430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-025-01297-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1007\/s11934-025-01297-x","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}